Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bemcentinib + Crizotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bemcentinib||BGB 324|BGB-324|BGB324|R428|R-428||AXL Inhibitor 29||Bemcentinib (BGB-324) is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120, PMID: 31134766).|
|Crizotinib||Xalkori||PF-02341066||ALK Inhibitor 31 BCR-ABL Inhibitor 29 MET Inhibitor 58 RON Inhibitor 11 ROS1 Inhibitor 20||Xalkori (crizotinib) inhibits ALK kinase, ALK fusion proteins, c-Met, ROS1 fusion proteins, and MST1R (RON), resulting in growth inhibition of tumor cells (PMID: 26951079, PMID: 22617245). Xalkori (crizotinib) is FDA approved for use in patients with ALK- or ROS1-positive (rearrangements and fusions) metastatic non-small cell lung cancer, in pediatric patients 1 year and older and young adults with relapsed or refractory, ALK-positive systemic anaplastic large cell lymphoma, and in adult and pediatric patients 1 year and older with ALK-positive, unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK F1174L AXL pos||neuroblastoma||sensitive||Bemcentinib + Crizotinib||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of Bemcentinib (BGB-324) to treatment with Xalkori (crizotinib) increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK F1174L in culture (PMID: 25450694).||25450694|
|EML4 - ALK AXL over exp||lung adenocarcinoma||predicted - sensitive||Bemcentinib + Crizotinib||Preclinical - Cell culture||Actionable||In a preclinical study, Bemcentinib (BGB-324) and Xalkori (crizotinib) combination treatment did not induce apoptosis, however, inhibited proliferation of Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL in culture (PMID: 32558295).||32558295|
|ALK R1275Q AXL pos||neuroblastoma||sensitive||Bemcentinib + Crizotinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the addition of Bemcentinib (BGB-324) to Xalkori (crizotinib) treatment increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture, and improved efficacy in xenograft models (PMID: 25450694).||25450694|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|